Beyond the paradox: Cardiac-specific miR-106a delivery as a translational turning point for heart failure?

References

[1] Goh RSJ, Chong B, Jayabaskaran J, et al. The burden of cardiovascular disease in Asia from 2025 to 2050: a forecast analysis for East Asia, South Asia, South-East Asia, Central Asia, and high-income Asia Pacific regions. Lancet Reg Health West Pac. 2024; 49:101138.

[2] Lu M, Cai S, Korolowicz K, et al. Reversing cardiac hypertrophy and heart failure using a cardiac targeting peptide linked to miRNA106a. Clin Transl Med. 2025; 15:e70432.

[3] Gallicano GI, Fu J, Mahapatra S, et al. Reversing cardiac hypertrophy at the source using a cardiac targeting peptide linked to miRNA106a: targeting genes that cause cardiac hypertrophy. Pharmaceuticals (Basel). 2022; 15: 871.

[4] Zahid M, Feldman KS, Garcia-Borrero G, et al. Cardiac targeting peptide, a novel cardiac vector: studies in bio-distribution, imaging application, and mechanism of transduction. Biomolecules. 2018; 8: 147.

[5] Feldman KS, Pavlou MP, Zahid M. Cardiac targeting peptide: from identification to validation to mechanism of transduction. Methods Mol Biol. 2021; 2211: 97-112.

[6] Sahagun DA, Lopuszynski JB, Feldman KS, et al. Toxicity studies of cardiac-targeting peptide reveal a robust safety profile. Pharmaceutics. 2024; 16: 73.

[7] Guan X, Wang L, Liu Z, et al. miR-106a promotes cardiac hypertrophy by targeting mitofusin 2. J Mol Cell Cardiol. 2016; 99: 207-217.

[8] Hao L, Wang J, Bi S-J, Cheng C. Upregulation of long noncoding RNA FGD5-AS1 ameliorates myocardial ischemia/reperfusion injury via microRNA-106a-5p and microRNA-106b-5p. J Cardiovasc Pharmacol. 2021; 78: e45-e54.

[9] Fei A, Li L, Li Y, et al. Diagnostic and prognostic value of plasma miR-106a-5p levels in patients with acute heart failure. J Cardiothorac Surg. 2024; 19: 261.

[10] Ovchinnikova ES, Schmitter D, Vegter EL, et al. Signature of circulating microRNAs in patients with acute heart failure. Eur J Heart Fail. 2016; 18: 414-423.

[11] Daneshpour M, Ghadimi-Daresajini A. Overview of miR-106a regulatory roles: from cancer to aging. Bioengineering (Basel). 202310: 892.

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Discovery published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.